Efficacy of Dapagliflozin on Early Diabetic Nephropathy and Its Effect on Serum MCP-1 and IL-6

Yi ZENG; Yun-juan LIAO; Ying LI; Zhen-kun HE

doi:10.12259/j.issn.2095-610X.S20211218

Volume 42 Issue 12

Dec. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2021 > 42(12): 41-46

Yi ZENG, Yun-juan LIAO, Ying LI, Zhen-kun HE. Efficacy of Dapagliflozin on Early Diabetic Nephropathy and Its Effect on Serum MCP-1 and IL-6[J]. Journal of Kunming Medical University, 2021, 42(12): 41-46. doi: 10.12259/j.issn.2095-610X.S20211218

Citation:

Yi ZENG, Yun-juan LIAO, Ying LI, Zhen-kun HE. Efficacy of Dapagliflozin on Early Diabetic Nephropathy and Its Effect on Serum MCP-1 and IL-6[J]. Journal of Kunming Medical University, 2021, 42(12): 41-46. doi: 10.12259/j.issn.2095-610X.S20211218

Citation:

PDF( 679 KB)

Efficacy of Dapagliflozin on Early Diabetic Nephropathy and Its Effect on Serum MCP-1 and IL-6

doi: 10.12259/j.issn.2095-610X.S20211218

Dept. of Nephrology，The 2nd Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650101，China

Received Date: 2021-09-15
Available Online: 2021-11-17
Publish Date: 2021-12-15

Abstract

Abstract

Objective To investigate the effect of Dapagliflozin in the treatment of early diabetic nephropathy and its effect on serum MCP-1 and IL-6. Methods 78 cases of patients with early diabetic nephropathy treated in our hospital from January 2019 to January 2020 were randomly divided into observation group and control group, with 39 cases in each group. Both groups received irbesartan and other conventional treatment. In addition, patients in the control group were treated with metformin, and patients in the observation group were treated with dagaglidine for 12 weeks. The changes of serum creatinine, fasting blood glucose （FBG）, 2 h postprandial blood glucose （2 h PG）, glycosylated hemoglobin （HbA1c）, urinary albumin excretion rate （UAER） and serum McP-1 and IL-6 levels in 2 groups were compared before and after treatment. Results After treatment, FBG, 2hPG and HbA1c in the two groups were significantly decreased, and the observation group was significantly lower than the control group （P < 0.05）. After treatment, UAER in both groups was significantly lower than before treatment, and the observation group was lower than the control group, the difference was statistically significant （P < 0.05）. There was no significant change in serum creatinine level in 2 groups before and after treatment （P > 0.05）. After treatment, the serum LEVELS of McP-1 and IL-6 in 2 groups were significantly decreased compared with before treatment, and the observation group was significantly lower than the control group, the difference was statistically significant （P < 0.05）. Pearson correlation analysis showed that UAER was positively correlated with serum MCP-1 and IL-6 in early diabetic nephropathy patients （P < 0.05）. Conclusion The application of Dapagliflozin in the treatment of early diabetic kidney disease can not only effectively control the blood glucose, but also reduce the serum MCP-1 and IL-6, reduce the leakage of urine protein, and then protect the renal function.
- Diabetic nephropathy,
- Dapagliflozin,
- Monocyte chemoattractant factor-1,
- Interleukin-6,
- Urinary albumin excretion rate

FullText(HTML)

References(25)

References

[1]	金莹,童林萍,沈培红. 糖尿病肾病进展机制及血糖波动、氧化应激状况的研究[J]. 中国基层医药,2017,24(13):1954-1958. doi: 10.3760/cma.j.issn.1008-6706.2017.13.009
[2]	刘蕊,戴岳. 糖尿病肾病发病机制的研究进展[J]. 药学与临床研究,2018,26(3):202-205.
[3]	Lin Y C,Chang Y H,Yang S Y,et al. Update of pathophysiology and management of diabetic kidney disease[J]. J Formos Med Assoc,2018,117(8):662-675. doi: 10.1016/j.jfma.2018.02.007
[4]	Haiyan Fu,Silvia Liu,Sheldon I Bastacky,et al. Diabetic kidney diseases revisited: A new perspective for a new era[J]. Molecular Metabolism,2019,30:250-263.
[5]	Gurley S B,Coffman T M. The Renin-Angiotensin System and Diabetic Nephropathy[J]. Seminars in nephrology,2007,27(2):144-152.
[6]	Scheen André J. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus[J]. Nature reviews Endocrinology,2020,16(10):555-577.
[7]	Dhillon S. Dapagliflozin:A review in type 2 diabetes[J]. Drugs,2019,79(10):1135-1146. doi: 10.1007/s40265-019-01148-3
[8]	张倩倩,叶启宝,陈丽,等. 达格列净治疗2型糖尿病肾病患者的临床疗效观察[J]. 医学理论与实践,2019,32(22):3591-3593.
[9]	中华医学会糖尿病分会. 中国2型糖尿病防治指南(2017年版)[J]. 中国实用内科杂志,2018,38(4):292-344.
[10]	GuariguataL,Whiting D,Hambleton I,et al. Global estimates of diabetes prevalence for 2013 and projections for 2035[J]. Diabetes Res Clin Pract,2014,103(2):137. doi: 10.1016/j.diabres.2013.11.002
[11]	况磊,陆菁. 糖尿病肾病的危险因素分析及血压的控制[J]. 中国实用医刊,2016,43(2):115-116. doi: 10.3760/cma.j.issn.1674-4756.2016.02.065
[12]	Shin S J,Chung S,Kim S J,et al. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor,Dapagliflozin,on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes[J]. Plos One,2016,11(11):e0165703.
[13]	魏志敏,马瑞霞,刘丽秋. 糖尿病肾病病理分型和肾组织内血管紧张素2表达的相关性分析[J]. 临床肾脏病杂志,2016,16(8):466-470.
[14]	Doshi S M,Friedman A N. Diagnosis and management of type 2 diabetic kidney disease[J]. Clin J Am Soc Nephrol,2017,12(8):1366-1373. doi: 10.2215/CJN.11111016
[15]	Ele Ferrannini,Silvia Jimenez Ramos,Afshin Sals,et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise:A randomized,double-blind,placebo-controlled,phase 3 trial[J]. Diabetes Care,2010,33(10):2217-2224. doi: 10.2337/dc10-0612
[16]	Johnston R,Uthman O,Cummins E,et al. Canagliflozin,dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes:Systematic review and economic evaluation[J]. Health Technol Assess,2018,21(2):219-220.
[17]	张伟华,李志龙,邱伟林,等. 达格列净对2型糖尿病伴代谢综合征患者血压、血糖和胆固醇的影响[J]. 黑龙江医学,2019,43(7):732-734. doi: 10.3969/j.issn.1004-5775.2019.07.011
[18]	Navarro J F,Mora C,Muros M,et al. Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients[J]. Nephrol Dial Transplant,2006,21(12):3428-3434. doi: 10.1093/ndt/gfl469
[19]	Abdelrahman A M,A l Suleimani Y,Shalaby A,et al. Effect of tocilizumab,an interleukin-6 inhibitor,on early stage streptozotocin-induced diabetic nephropathy in rats[J]. Naunyn Schmiedebergs Arch Pharmacol,2019,392(8):1005-1013. doi: 10.1007/s00210-019-01655-w
[20]	Krystallenia Alexandraki,Christina Piperi,Christos Kalofoutis,et al. Inflammatory process in type 2 diabetes:The role of cytokines[J]. Ann N Y Acad Sci,2006,1084(1):89-117. doi: 10.1196/annals.1372.039
[21]	阳皓,谭巧灵,王岑,等. 达格列净对早期2型糖尿病肾病患者尿微量白蛋白和促炎症因子的影响[J]. 华中科技大学学报(医学版),2019,48(4):400-404.
[22]	Naoto Terami,Daisuke Ogawa,Hiromi Tachibana,et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor,dapagliflozin,ameliorates glucose homeostasis and diabetic nephropathy in db/db mice[J]. PLoS One,2014,9(6):100777. doi: 10.1371/journal.pone.0100777
[23]	Hatanaka Takashi,Ogawa Daisuke,Tachibana Hiromi,et al. Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice[J]. Pharmacology Research & Perspectives,2016,4(4):00239.
[24]	H J L Heerspink,E Johnsson,I Gause-Nilsson,et al. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers[J]. Diabetes Obes Metab,2016,18(6):590-597. doi: 10.1111/dom.12654
[25]	Christoph Wanner,Silvio E Inzucchi,John M Lachin,et al. Empagliflozin and progression of kidney disease in Type 2 diabetes[J]. N Engl J Med,2016,375(4):323-334. doi: 10.1056/NEJMoa1515920

Relative Articles(20)

Relative Articles

[1]	Xiao CHEN. Development of Predictive Scale for Diabetic Kidney Disease Progression Based on Decision Tree Classification Model. Journal of Kunming Medical University, 2024, 45(8): 109-116. doi: 10.12259/j.issn.2095-610X.S20240816
[2]	Jing ZHOU, Linling LI, Haihong WANG, Yuqiong YANG. Effect and Psychological State of Triangle Hierarchical Management+LEARNS Model for Diabetes Nephropathy. Journal of Kunming Medical University, 2024, 45(4): 197-202. doi: 10.12259/j.issn.2095-610X.S20240429
[3]	Mengdan XU, Hong XIANG, Xiaolong GAO, Jin ZHANG, Haiyan WU, Lilin WANG. Effect of Dapagliflozin on Cardiac Structure and Function in Patients with Heart Failure Due to Mildly Reduced Ejection Fraction. Journal of Kunming Medical University, 2024, 45(11): 95-102. doi: 10.12259/j.issn.2095-610X.S20241114
[4]	Mengxue LIU, Jia MIAO, Xuehe SHENG. Correlation between Blood UA，Smad1 Protein，Urine mALB Levels and the Therapeutic Effect of Dapagliflozin in Patients with Type 2 Diabetes Nephropathy. Journal of Kunming Medical University, 2024, 45(4): 170-176. doi: 10.12259/j.issn.2095-610X.S20240425
[5]	Ling ZHAO, Hongling ZHONG, Xinru GAO, Mei LI, Tingting MAO, Rongyong LI, Tingyu KE. Clinical Observation of SGLT-2 Inhibitors in Delaying the Progression of Diabetic Nephropathy. Journal of Kunming Medical University, 2023, 44(5): 60-65. doi: 10.12259/j.issn.2095-610X.S20230527
[6]	Guo-qiang XUE, Xin-xin WEI, Na YAO, Wen-hua ZHAO. Metformin Protects Type II Diabetic Kidneys by Regulating PARP-1 Activity. Journal of Kunming Medical University, 2021, 42(6): 29-37. doi: 10.12259/j.issn.2095-610X.S20210632
[7]	Xiang Xi , Li Wan Bi , Zhang Xian , Liu Hua , Wang Yu Ming , Yang Cai , Bai Yun Xia . Correlation between Vitamin D Receptor (VDR) Gene ApaⅠ, BsmⅠ Single Nucleotide Polymorphism and Diabetic Kidney Disease in Type 2 Diabetic Patients. Journal of Kunming Medical University, 2017, 38(08): 79-85.
[8]	Yang Dan . Effect of Paracrine Function of Mesenchymal Stem Cells on Diabetic Nephropathy. Journal of Kunming Medical University,
[9]	Xiang Xi . The Correlation between Vitamin D Receptor Gene FokI Single Nucleotide Polymorphism and Diabetic Kidney Disease. Journal of Kunming Medical University,
[10]	An Xin Huan . . Journal of Kunming Medical University,
[11]	Li Hui Fang . . Journal of Kunming Medical University,
[12]	Zhang Xi Jun . . Journal of Kunming Medical University,
[13]	Xiang Xi . . Journal of Kunming Medical University,
[14]	Ma Wei Jiang . . Journal of Kunming Medical University,
[15]	Ma Cheng Bin . . Journal of Kunming Medical University,
[16]	Wang Xing Ning . . Journal of Kunming Medical University,
[17]	Du Xing Hua . . Journal of Kunming Medical University,
[18]	Lu Fang Li . . Journal of Kunming Medical University,
[19]	Tang Li Li . . Journal of Kunming Medical University,
[20]	Li Mei Rui . . Journal of Kunming Medical University,